Goserelin acetate

Base Information

• Chemical Name: Goserelin acetate
• CAS No.: 145781-92-6
• Molecular Formula: C59H84N18O14^.C2H4O2
• Molecular Weight: 1269.41
• Hs Code.: 2937190000
• Mol file: 145781-92-6.mol

Synonyms:[t-BuDSer6,: AzaGly10]-LH-RH;1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-D-serine]-, 2-(aminocarbonyl)hydrazide, acetate (salt);Zoladex (TN);

Chemical Property of Goserelin acetate

Chemical Property:

• Appearance/Colour: white crystalline powder
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: >190°C (dec.)
• Boiling Point: 1695.5 °C at 760 mmHg
• Flash Point: 979.2 °C
• PSA: 493.39000
• LogP: 2.78000
• Storage Temp.: −20°C
• Solubility.: H2O: 20 mg/mL, clear, colorless

Purity/Quality:

98% ^*data from raw suppliers

Goserelin acetate ^*data from reagent suppliers

Safty Information:

• Safety Statements: 22-24/25

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Description: Goserelin acetate, like leuprolide acetate, is a synthetic superagonist nonapeptide analogue of GnRH that possesses greater potency than the natural hormone. Note that it contains D-Ser(But) and NH-NHCONH2 in place of Gly6 and Gly10-NH2, respectively. That is, the C terminal modification simply has an NH substituting for the CH2 of Gly, and like the C-terminal change in leuprolide acetate, this inhibits enzymatic degradation of the peptide by the postproline carboxyamide peptidase. Goserelin acetate is available in the form of a small, solid pellet that is administered as an SC implant for the palliative treatment of advanced, metastatic breast cancer in pre- and perimenopausal women or, similarly, as a palliative in advanced prostatic cancer. The rationale for this drug's use is, as described above, its ability as a superagonist to bring the levels of estradiol or testosterone to near castrate levels, thus slowing the progression of breast or prostate carcinoma, respectively. Additionally, goserelin acetate is approved for use in treating endometriosis for up to 6 months. Goserelin is a synthetic gonadotropin-releasing hormone (GNRH) agonist that binds to the GNRH receptor (GNRHR; Ki = 1.6 nM, in CHO cells expressing the human receptor). It binds to mouse pituitary αT3-1 cells and human placenta (Kds = 2 and 580 nM, respectively) and increases intracellular calcium in αT3-1 cells. Goserelin induces testosterone production in vitro within 4 h in rat Leydig cells (ED50 = 83 nM) but decreases testosterone plasma level in vivo in rats over a period of 2 to 24 weeks. It inhibits tumor growth in a DU145 human prostate carcinoma mouse xenograft model when administered at a dose of 100 μg per day. Formulations containing goserelin have been used in the treatment of hormone-dependent breast and prostate cancers, as well as endometriosis and uterine fibroids.
• Uses: Anticancer injectable gonadotropin releasing hormone superagonist (GnRH agonist) or luteinizing hormone antiproliferative activity in breast, prostate and endometrial cancers Synthetic peptide agonist analog of LH-RH. Antineoplastic (hormonal).
• Clinical Use: Goserelin acetate also is used in combination with the antiandrogen flutamide for shrinking prostate carcinoma before radiation therapy. This maximal androgen blockade combination is used when the prostate carcinoma has been staged as locally confined to the prostate gland, with one or both lobes as well as the seminal vesicles involved. The treatment should start 8 weeks before radiation treatment begins and be continued throughout the radiation therapy. Furthermore, women who are to undergo hysterectomy for menorrhagia can benefit from previous treatment with goserelin acetate, because it is able to induce endometrial thinning. This thinning of the endometrium improves the operating environment by causing less intrauterine bleeding, increased postoperative amenorrhea, and decreased dysmenorrhea following surgery, which is why goserelin acetate is approved for inducing endometrial thinning prior to a patient undergoing a hysterectomy for heavy menstrual bleeding.